Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
AJ Cooper, LV Sequist, JJ Lin - Nature Reviews Clinical Oncology, 2022 - nature.com
The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …
Targeting ALK: precision medicine takes on drug resistance
JJ Lin, GJ Riely, AT Shaw - Cancer discovery, 2017 - AACR
Anaplastic lymphoma kinase (ALK) is a validated molecular target in several ALK-
rearranged malignancies, including non–small cell lung cancer. However, the clinical …
rearranged malignancies, including non–small cell lung cancer. However, the clinical …
Light-induced control of protein destruction by opto-PROTAC
By hijacking endogenous E3 ligase to degrade protein targets via the ubiquitin-proteasome
system, PROTACs (PRoteolysis TArgeting Chimeras) provide a new strategy to inhibit …
system, PROTACs (PRoteolysis TArgeting Chimeras) provide a new strategy to inhibit …
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer
I Mota, E Patrucco, C Mastini, NR Mahadevan, TC Thai… - Nature Cancer, 2023 - nature.com
Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) is
treated with ALK tyrosine kinase inhibitors (TKIs), but the lack of activity of immune …
treated with ALK tyrosine kinase inhibitors (TKIs), but the lack of activity of immune …
FDA-approved small-molecule kinase inhibitors
P Wu, TE Nielsen, MH Clausen - Trends in pharmacological sciences, 2015 - cell.com
Kinases have emerged as one of the most intensively pursued targets in current
pharmacological research, especially for cancer, due to their critical roles in cellular …
pharmacological research, especially for cancer, due to their critical roles in cellular …
Systems and synthetic microRNA biology: from biogenesis to disease pathogenesis
H Matsuyama, HI Suzuki - International journal of molecular sciences, 2019 - mdpi.com
MicroRNAs (miRNAs) are approximately 22-nucleotide-long, small non-coding RNAs that
post-transcriptionally regulate gene expression. The biogenesis of miRNAs involves multiple …
post-transcriptionally regulate gene expression. The biogenesis of miRNAs involves multiple …
In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system
Chromosomal rearrangements have a central role in the pathogenesis of human cancers
and often result in the expression of therapeutically actionable gene fusions. A recently …
and often result in the expression of therapeutically actionable gene fusions. A recently …
Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase
We explored the utility of targeting anaplastic lymphoma kinase (ALK), a cell surface
receptor overexpressed on pediatric solid tumors, using chimeric antigen receptor (CAR) …
receptor overexpressed on pediatric solid tumors, using chimeric antigen receptor (CAR) …
ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
X Du, Y Shao, HF Qin, YH Tai, HJ Gao - Thoracic cancer, 2018 - Wiley Online Library
The ALK gene encodes a transmembrane tyrosine kinase receptor. ALK is physiologically
expressed in the nervous system during embryogenesis, but its expression decreases …
expressed in the nervous system during embryogenesis, but its expression decreases …
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers
R Katayama, AT Shaw, TM Khan… - Science translational …, 2012 - science.org
Most anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancers (NSCLCs)
are highly responsive to treatment with ALK tyrosine kinase inhibitors (TKIs). However …
are highly responsive to treatment with ALK tyrosine kinase inhibitors (TKIs). However …